ITM Isotope Technologies Munich SE: ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma

Garching/Munich, Munich and Münster, Germany, March 13, 2023 - ITM Isotope Technologies Munich SEand the Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster today announced

Related Keywords

Germany ,Neuherberg ,Bayern ,Garching ,Munich ,Dennis Riedl ,Reinhard Zeidler ,Ben Orzelek ,Walter Stummer ,Thomas Bauer ,Verena Coscia ,Steffen Schuster ,Julia Hofmann Svenja ,Department Of Neurosurgery ,University Hospital ,Nuclear Medicine ,Corporate Communications ,Helmholtz Association ,Technologies Munich ,Targeted Radionuclide Therapy ,Helmholtz Munich ,Radionuclide Therapy ,Prof Walter Stummer ,Principal Investigator ,Project Leader ,Brain Tumor ,Isotope ,Technologies ,Helmholtz ,University ,Hospital ,M 252 Nster ,Nnounce ,Start ,Hase ,Linical ,Trial ,Adiotherapeutic ,Glioblastoma ,